Publications

2015:

  1. Shelton SE, Lee YZ, Lee M, Cherin E, Foster FS, Aylward SR, Dayton PA. Quantification of Microvascular Tortuosity During Tumor Evolution Using Acoustic Angiography. Ultrasound Med Biol. 2015 Jul;41(7):1896-904. [link]
  2. He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, Kabanov AV, Luxenhofer R. Poly(2-oxazoline) Based Micelles with High Capacity for 3rd Generation Taxoids: Preparation, In Vitro and In Vivo Evaluation. J Control Release. 2015 Jun 28;208:67-75. [link]
  3. Carson CC, Moschos SJ, Edminston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE. IL2 Inducible T-Cell Kinase, a Novel Therapeutic Target in Melanoma. Clin Cancer Res. 2015 May 1;21(9):2167-76. [link]
  4. Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 Apr;14(4):920-30. [link]
  5. Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local Iontophoretic Administration of Cytotoxic Therapies to Solid Tumors. Sci Transl Med. 2015 Feb 4;7(273):273ra14. [link]
  6. Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr DB, Pardo-Manuel de Villena F, Kim WY, Magnuson T. Coexistent ARID1A-PIK3CA Mutations Promote Ovarian Clear-Cell Tumorigenesis Through Pro-Tumorogenic Inflammatory Cytokine Signalling. Nat Commun. 2015 Jan 27;6:6118. [link]

2014:

  1. Sundaram S, Freemerman AJ, Galanko JA, McNaughton KK, Bendt KM, Darr DB, Troester MA, Makowski L. Obesity-Mediated Regulation of HGF/c-Met is Associated with Reduced Basal-like Breast Cancer Latency in Parous Mice. PLoS One. 2014 Oct 29;9(10):e111394. [link]
  2. Howe MK, Bodoor K, Carlson DA, Hughes PF, Alwarawrah Y, Loiselle DR, Jaeger AM, Darr DB, Jordan JL, Hunter LM, Molzberger E, Gobillot TA, Thiele DJ, Brodsky JL, Spector NL, Haystead TA. Identification of an Allosteric Small-Molecule Inhibitor Selective for the Inducible Form of Heat Shock Protein 70. Chem Biol. 2014 Dec 18;21(12):1648-59. [link]
  3. Song G, Darr DB, Santos C, White T, Jordan J, Kim Mimi, Midkiff B, Feinberg N, Miller R, Rogers A, Dudley A, Perou CM and Zamboni WC. Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. Clin Cancer Res. 2014 Dec 1;20(23):6083-95. [link]
  4. Burd C, Clark K, Martin B, Fu K, Jeck W, Souroullas G and Sharpless N. Mutation-Specific RAS Oncogenicity Explains N-RAS Codon 61 Selection in Melanoma. Cancer Discov. 2014 Dec;4(12):1418-29. [link]
  5. Sundaram S, Le T, Essaid L, Freemerman A, Huang M, Galanko J, McNaughton KK, Bendt K, Darr DB, Troester M and Makowski L. Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and Basal-Like Breast Cancer Progression. Front Oncol., 2014 Jul 8;4:175. [link]
  6. Sanoff H, Deal A, Krishnamurthy K, Torrice C, Dillon P, Sorrentino J, Ibrahim J, Jolly J, Williams G, Carey L, Drobish A, Gordon B, Alston B, Hurria A, Kleinhans K, Rudolph K, Sharpless NE and Muss H. Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. J Natl Cancer Inst. 2014 Apr 1;106(4). [link]
  7. Zhou B*, Damrauer J*, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee C, Troester M, Miller R, Jin J  Darr D, Perou C, Levine R, Diehn M and Kim W.  Erythropoietin promotes breast cancer tumorigenesis through tumor initiating cell self-renewal.  J Clin Invest. 2014 Feb 3;124(2):553-63. [link]

2013:

  1. Chan K, Jones S, Brighton H, Bo T, Cochran S, Sharpless NE and Bear JE. Intravital imaging of a spheroid-based orthotopic model of melanoma in the mouse ear skin. 2013. IntraVital, 2:2, e25805. [link]
  2. Sundaram S*, Freemerman AJ*, Johnson AR, Miner JJ, McNaughton K, Galanko J, Bendt KM, Darr DB, Perou CM Troester MA and Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basallike breast cancer.  Breast Cancer Research and Treatment. 2013 Nov 12. [link]
  3. Usary JE, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges AS, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless N, Perou CM. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res. 2013 June 18. [link]
  4. Burd C, Sorrentino J, Clark K, Darr DB, Krishnamurthy J, Deal A, Bardessey N, Castrillion D, Beach D, Sharpless NE. Monitoring Tumorigenesis and Senescence In Vivo with a p16(INK4a)-Luciferase Model. Cell. 2013 Jan 17;152(1-2):340-51. [link]
  5. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and Non-Canonical NF-κB Signaling Promotes the Function of Basal-Like Breast Cancer Tumor-Initiating Cells. Oncogene. 2013 Mar 11. [link]
  6. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HF1a and HIF2a independently activate SRC to promote melanoma invasion and metastases. J Clin Invest. 2013 Apr 8. [link]
  7. Anders C, Adamo B, Karginova O, Deal A, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller R, Perou C, Sharpless N and Zamboni W. Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. Plos One. 2013 May 1. [link]

2012:

  1. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. J Natl Cancer Inst 2012;104:1–11. [link]
  2. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18;483(7391):613-7. [link]
  3. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL.. Targeted MEK1/2 Inhibition Induces a Dynamic Reprogramming of the Kinome In Triple Negative Breast Cancer. Cell. Apr 2012 13;149(2):307-21. [link]
  4. The Collaborative Cross Consortium. The Genome Architecture of the Collaborative Cross Mouse Genetic Reference. Genetics. 2012 Feb; 190(2):389-401. [link]
  5. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined therapy with PI3K/mTOR and MEK Inhibitors Exhibits Broad Anti-Tumor activity in Faithful Murine Cancer Models. Clin Cancer Res. 2012 Oct 1;18(19):5290-303.[link]
  6. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE.  LKB1/STK11 Inactivation Leads to Expansion of Pro-Metastatic Tumor Sub-Population in Melanoma. Cancer Cell. 2012 Jun 12;21(6):751-64.[link]
  7. Kim WY and Sharpless NE. Drug Efficacy Testing In Mice. In Kinase Inhibitors and Cancer, I Mellinghoff and C Sawyers, eds. In Press, 19 type pages.
  8. Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC. Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. Oncologist. 2012 Sep 19. [link]

    2011:

    1. Liu Y, Johnson SM, Fedoriw Y, Rogers A, Yuan H, Krishnamurthy J, Sharpless NE. Expression of p16INK4a prevents cancer and promotes aging in lymphocytes. Blood, 2011; 117:3257-67. [link]
    2. Cardenas JC, Owens AP, Krishnamurthy J, Sharpless NE, Whinna HC and Church FC. Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler. Thromb. Vasc. Biol., 2011, In Press. [link]
    3. Siamakpour-Reihani S, Caster J, Bandhu Nepal D, Courtwright A, Hilliard E, Usary J, Ketelsen D, Darr D, Shen XJ, Patterson C, Klauber-Demore N.. The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus. PLoS One. 2011;6(6):e20412. Epub 2011 Jun 3. [link]
    4. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. Epub 2011 Jun 1. [link]
    5. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco S, Roche O, Heathcote SA, Chow VWK, Greer SN, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M, Loss of JAK2 regulation via VHL-SOCS1 E3 ubiquitin heterocomplex underlies chuvash polycythemia. Nat Med, 2011 Jun 19;17(7):845-53. [link]

     

      2010-2007:

      1. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, Garcia-Echeverria C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010;17:547-559. [link]
      2. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, Ramsey MR, Jin J, Wong KK, Su L, Zhou D, Sharpless NE. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest. 2010;120:2528-2536. [link]
      3. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, Horner J, Depinho RA, Sharpless NE. Somatic p16INK4a loss accelerates melanomagenesis. Oncogene. Aug. 9th, 2010. [link]
      4. Rozenberg GI, Monahan KB, Torrice C, Bear JE, Sharpless NE. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res. 2010; 20:361-71 [link]
      5. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG, Wong KK. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest, 2009; 119: 2160-70. [link]
      6. Li W, Asokan A, Wu Z, Van Dyke T, Diprimio NJSJ, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Eugene-Redmond D, Petermann K, Sharpless NE, Samulski J. Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Mol Ther. May, 2008, 16:1252-60 [link]
      7. Ji H, Ramsey MR. Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera S, Liang MC, Cai D, Naumov GN, Bao L, Contreras C, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera R, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Jänne PA, Johnson B, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448:807-810. [link]
      Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. Epub 2011 Jun 1.